Cancer Survival Rates Are the Highest They’ve Been since the 1970s

The American Cancer Society reports a record five‑year relative survival rate of 70% for U.S. cancer patients diagnosed 2015–2021, driven by improved detection, targeted therapies and reduced smoking; myeloma survival rose from 32% in the 1990s to 62% and liver cancer from 7% to 22%. The ACS projects more than 2 million new cancer diagnoses and over 625,000 deaths in 2026, with lung cancer causing the most fatalities, and warns that early 2025 National Cancer Institute grant funding fell ~31% year-over-year—cuts that could constrain future R&D and access to therapies, with implications for healthcare and biotech investment trends.

Analysis

Market structure: Improved five-year survivorship (70% for 2015–21) reweights oncology from acute episodic spend to chronic care, boosting demand for oral targeted agents, maintenance immunotherapies, diagnostics/NGS and specialty pharmacy services over the next 3–5 years. Winners are large-cap pharmas with durable franchises (MRK, BMY, GILD) and diagnostics/NGS plays (ILMN, GH, EXAS); losers are cash‑constrained small biotechs reliant on grant funding and single‑asset oncology names. Pricing power will be bifurcated—big players can sustain premium pricing but face payer negotiation risk if utilization rises >10–20% year-over-year.

Risk assessment: Tail risks include abrupt federal funding cuts (NCI grants down 31% YTD), Medicare reimbursement changes or ADUFA‑style pricing mandates—each could shave 10–30% off small-cap biotech valuations within 3–12 months. Hidden dependencies: survivorship gains depend on continuous approval flow and NGS adoption; supply constraints (CAR‑T manufacturing) and reimbursement caps are second‑order risks that materialize over 6–24 months. Catalysts to monitor: congressional budget votes (next 60–120 days), FDA oncology approvals cadence, ASCO/ESMO conference readouts.

Trade implications: Favor 12–24 month long core positions in ILMN and GH for durable secular testing growth, and concentration-weighted positions in MRK/BMY for immuno/targeted revenue — hedge with index puts on XBI/XBI put spreads ahead of budget votes. Rotate out of XBI/small‑cap baskets and reallocate to diagnostics and big‑pharma; expect 20–40% relative upside on diagnostics if screening upticks. Use options to time around regulatory and funding catalysts (3–9 month expiries).

Contrarian angles: The market underprices diagnostics leverage—incremental screening that raises detectability by 5–10% annually could translate to 15–30% revenue lift for NGS players over 2 years, while overpricing survivorship as unalloyed upside ignores payer pushback. Conversely, consensus may overrate small‑cap clinical stories; bankrun-style derisking (trial misses) could cascade through funding‑dependent names. Historical parallel: post‑2000 precision‑medicine rotation shows durable winners concentrate in platform/scale rather than single‑asset biotechs.

Key Decisions for Investors

• Establish a 2.5% portfolio long over 12–24 months: 1.0% ILMN (Illumina), 0.8% GH (Guardant Health), 0.7% EXAS (Exact Sciences). Thesis: secular NGS/screening tailwinds; target +25–40% upside in 12–24 months. Set initial stop-loss at -25% per name and trim to take profits at +30–40%.
• Allocate 3.0% portfolio to large-cap oncology equities over 6–12 months: 1.5% MRK (Merck), 1.0% BMY (Bristol‑Myers Squibb), 0.5% GILD (Gilead). Rationale: durable immuno/targeted cash flows and CAR‑T/IP exposure; target 12–24% upside. Use covered calls (sell 3–6 month calls at +15–25% OTM) to finance carry if implied vol remains elevated.
• Reduce small‑cap biotech exposure (XBI/IBB) by 40% within 30 days and redeploy proceeds to diagnostics and large‑cap pharmas. Rationale: NCI funding uncertainty (‑31% YTD) elevates cash‑runway default risk; trimming reduces tail‑risk while preserving market upside.
• Purchase a protective 3–6 month put spread on XBI sized to hedge ~3% portfolio exposure (buy 6–9% OTM puts, sell 3–6% OTM puts) ahead of key budget votes and FDA conference windows (next 60–120 days). Rationale: asymmetric hedge versus funding/regulatory catalyst risk; cost limited by sold leg.